Wasem Alsabbagh shows that universal pharmacare is the natural product of the core values of Canada’s health care system and that it is cost-saving.
Since the 1960s, five national commissions have recommended universal pharmacare for Canada. The most recent of these is the detailed and strategic report of the Advisory Council on the Implementation of National Pharmacare. Now, after more than 50 years of waiting, Canada is close to adding prescription drugs to our “medicare” system. This is extremely […]
Naila Ramji advocates for the importance of clinical trial transparency.
Marc-André Gagnon urges modernization and fairness in the pricing of patented drugs in Canada
Deborah Gleeson and Ronald Labonté object to lengthening market exclusivity for biologic medicines in the United States-Mexico-Canada Agreement.
Marc-André Gagnon dispels misconceptions about the benefits of private health insurance plans and argues in favour of a universal model for pharmacare.
Andrea Frydl cautions Canadians about the harms of direct-to-consumer advertising for pharmaceuticals and offers advice for health care providers and policy makers.